Results 171 to 180 of about 20,735 (212)

Immunogenicity and safety to SARS-Cov-2 vaccination in patients with systemic vasculitis. [PDF]

open access: yesFront Immunol
Biegelmeyer E   +48 more
europepmc   +1 more source

Evaluation of Reactogenicity and Neutralizing Antibody Responses 6 Months Post-Vaccination with Monovalent COVID-19 Vaccine. [PDF]

open access: yesInfect Chemother
Lim SY   +12 more
europepmc   +1 more source

Vaccine Platform-Dependent Differential Impact on Microbiome Diversity: Potential Advantages of Protein Subunit Vaccines. [PDF]

open access: yesVaccines (Basel)
Seong H   +8 more
europepmc   +1 more source

Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222). [PDF]

open access: yesEBioMedicine
Belij-Rammerstorfer S   +26 more
europepmc   +1 more source

Effectiveness of ChAdOx1 nCoV-19 (Vaxzevria) primary series vaccine against SARS-CoV-2 beta and delta variants: a nationwide study. [PDF]

open access: yesBMC Infect Dis
Chemaitelly H   +21 more
europepmc   +1 more source

Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial. [PDF]

open access: yesEClinicalMedicine
Rumyantsev A   +25 more
europepmc   +1 more source

Kinetics of cellular immune response to SARS-CoV-2 vaccine boosters in dialysis and kidney transplant patients without infection. [PDF]

open access: yesJ Bras Nefrol
Souza RM   +5 more
europepmc   +1 more source

Identification of novel genetic biomarkers for ChAdOx1 nCoV-19 mediated immunogenicity. [PDF]

open access: yesFront Immunol
Chou WH   +21 more
europepmc   +1 more source

SARS-CoV-2 vaccines elicit differential Fc effector functions. [PDF]

open access: yesiScience
Manamela NP   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy